Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer Resistant to Endocrine Therapy

NCT03007992 is registered in ClinicalTrials.gov with Johannes Gutenberg University Mainz as lead sponsor.

NCT NCT03007992
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03007992 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer Resistant to Endocrine Therapy
Lead sponsor
Johannes Gutenberg University Mainz
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2016
Completion date
March 2, 2019
Enrollment
9 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer